Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars

Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars

Aim. To define the frequency of adverse events and loss of the response in patients with ulcerative colitis (UC) and Crohns disease (CD), treated with original medicine infliximab (IFX) Remicaide and its biosimilars. Materials and methods. We included 154 patients with IBD: 78 UC patients (50.6%)...

Cijeli opis

Bibliografski detalji
Glavni autori: O. V. Knyazev, M. Yu. Zvyaglova, A. V. Kagramanova, I. A. Li, E. A. Sabelnikova, A. A. Lishchinskaya, D. S. Kulakov, A. I. Parfenov
Format: Članak
Jezik:Russian
Izdano: "Consilium Medicum" Publishing house 2021-02-01
Serija:Терапевтический архив
Teme:
biosimilar
crohn’s disease
inflammatory bowel disease
infliximab
ulcerative colitis
Online pristup:https://ter-arkhiv.ru/0040-3660/article/viewFile/64705/47582

Internet

https://ter-arkhiv.ru/0040-3660/article/viewFile/64705/47582

Slični predmeti